These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37954899)

  • 21. Correlation Among Antifactor Xa, Activated Partial Thromboplastin Time, and Heparin Dose and Association with Pediatric Extracorporeal Membrane Oxygenation Complications.
    McMichael ABV; Hornik CP; Hupp SR; Gordon SE; Ozment CP
    ASAIO J; 2020 Mar; 66(3):307-313. PubMed ID: 30883406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
    Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
    Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concordance Between Active Partial Thromboplastin Time and Anti-Factor Xa Assays in Neurocritically Ill Patients Receiving Subcutaneous Heparin Prophylaxis.
    Shinn G; Berger K; Roh D; Doyle K; Boehme AK; Connolly ES; Park S; Agarwal S; Claassen J; Der-Nigoghossian C
    Neurohospitalist; 2023 Jul; 13(3):221-227. PubMed ID: 37441213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
    Rizk E; Wilson AD; Murillo MU; Putney DR
    Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support.
    Li S; Li A; Beckman JA; Kim C; Granich MA; Mondin J; Sabath DE; Garcia DA; Mahr C
    ESC Heart Fail; 2024 Oct; 11(5):2742-2748. PubMed ID: 38725133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of routine laboratory measures of heparin anticoagulation for neonates on extracorporeal membrane oxygenation.
    Sulkowski JP; Preston TJ; Cooper JN; Duffy VL; Deans KJ; Chicoine LG; Minneci PC
    J Extra Corpor Technol; 2014 Mar; 46(1):69-76. PubMed ID: 24779122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudo Heparin Resistance After Pulmonary Endarterectomy: Role of Thrombus Production of Factor VIII.
    Nykänen AI; Selby R; McRae KM; Zhao Y; Asghar UM; Donahoe L; Granton J; de Perrot M
    Semin Thorac Cardiovasc Surg; 2022; 34(1):315-323. PubMed ID: 33984481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing Anticoagulation in Neonates With Congenital Diaphragmatic Hernia During Extracorporeal Membrane Oxygenation: Does Anti-Factor Xa or Thromboelastometry Provide Additional Benefit?
    Perez Ortiz A; Dempfle CE; Jung T; Doniga T; Weiß C; Hetjens S; Schaible T; Rafat N
    Front Pediatr; 2021; 9():685906. PubMed ID: 34604133
    [No Abstract]   [Full Text] [Related]  

  • 30. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation.
    Figueroa Villalba CA; Brogan TV; McMullan DM; Yalon L; Jordan DI; Chandler WL
    Crit Care Med; 2020 Dec; 48(12):e1179-e1184. PubMed ID: 33009103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO.
    Streng AS; Delnoij TSR; Mulder MMG; Sels JWEM; Wetzels RJH; Verhezen PWM; Olie RH; Kooman JP; van Kuijk SMJ; Brandts L; Ten Cate H; Lorusso R; van der Horst ICC; van Bussel BCT; Henskens YMC
    TH Open; 2020 Oct; 4(4):e365-e375. PubMed ID: 33235946
    [No Abstract]   [Full Text] [Related]  

  • 33. A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy.
    Liu Y; Yuan Z; Han X; Song K; Xing J
    Hamostaseologie; 2023 Jun; 43(3):171-178. PubMed ID: 35882351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study.
    Panigada M; E Iapichino G; Brioni M; Panarello G; Protti A; Grasselli G; Occhipinti G; Novembrino C; Consonni D; Arcadipane A; Gattinoni L; Pesenti A
    Ann Intensive Care; 2018 Jan; 8(1):7. PubMed ID: 29340875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.
    Mahmoud L; Zullo AR; McKaig D; Berard-Collins CM
    R I Med J (2013); 2016 Mar; 99(3):33-7. PubMed ID: 26929970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?
    Nguyen TP; Phan XT; Huynh DQ; Viet Truong HT; Hai Le YN; Nguyen TM; Minh Du QQ; Le TP; Truong HN; Ho TT; Ngoc Pham TT
    Crit Care Res Pract; 2021; 2021():5579936. PubMed ID: 34055407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should we abandon the APTT for monitoring unfractionated heparin?
    Arachchillage DRJ; Kamani F; Deplano S; Banya W; Laffan M
    Thromb Res; 2017 Sep; 157():157-161. PubMed ID: 28759760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Time Within Therapeutic Range Using Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children.
    Haftmann RJ; Pineda EM; Hall BA; Wilson MD; Mateev SN
    J Pediatr Pharmacol Ther; 2023; 28(3):228-234. PubMed ID: 37303766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.